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1155Epidemiological studies, Mendelian genetic disorders,
genome-wide association studies with more common genetic
variants, and clinical trials have clearly established low-density
lipoprotein cholesterol (LDL-C) as the major target for lipid-
modifying therapy. Statins are the standard of care, supported
by a large body of data demonstrating robust effectiveness in
lowering LDL-C and in reducing the risk for cardiovascular
disease (1,2). However, many individuals at risk for cardio-
vascular disease fail to achieve LDL-C goals (3,4). Only a
relatively few number of alternative, nonstatin agents have
been approved for lowering LDL-C levels, and their
LDL-C–lowering efﬁcacy is modest. Therefore, physicians
and their patients are looking for additional therapeutic
options.
See page 1163
ETC-1002 (8-hydroxy-2,2,14,14-tetramethylpentadeca-
nedioic acid) is currently in Phase II clinical development,
primarily to treat hypercholesterolemia, with early support
for potentially favorable effects on other cardiometabolic
risk factors, such as insulin sensitivity, inﬂammatory markers,
and blood pressure. ETC-1002 modulates two distinct
and complementary molecular targets: 1) hepatic adenosine
triphosphate-citrate lyase (ACL) and 2) adenosine mono-
phosphate-activated protein kinase (AMPK) (5). Inhibition
of ACL by ETC-1002 rapidly reduces levels of acetyl
coenzyme A (CoA) (5), the ﬁnal common substrate for both
fatty acid and sterol synthesis, at a point in the lipid synthesis
pathway well upstream of 3-hydroxy-3-methylglutaryl
(HMG)-CoA reductasedthe molecular target of statins.
In a manner complementary to the effects of ACL,
activation of AMPK results in inhibitory phosphorylation of
acetyl-CoA carboxylase and HMG-CoA reductase (5).
ETC-1002, via effects at multiple points within the lipid-
synthesis pathway, inhibits sterol and fatty acid synthesis
and increases mitochondrial long-chain fatty acid oxidation.
Furthermore, ETC-1002–mediated AMPK activation
also improves glucose regulation (5). In animal models,
ETC-1002 improved plasma cholesterol and triglycerides;
hepatic fat; inﬂammatory markers; glycemic control;
blood pressure; and, notably, atherosclerosis (5–8). Phase I
human studies of single-dose tolerability up to 250 mg and
multiple-dose tolerability up to 220 mg/day (n ¼ 77)
revealed no dose-limiting adverse effects, and the drug was
generally well tolerated (data on ﬁle). The aim of this ﬁrst
Phase II clinical trial was to evaluate the lipid-altering
efﬁcacy and safety of a range of doses of ETC-1002 in
individuals with hypercholesterolemia with or without
elevated triglyceride levels. Subgroup analyses were also
performed regarding other cardiometabolic risk factors.
Methods
Study design. BetweenDecember2010 andAugust 2011, this
randomized, double-blind, placebo-controlled, parallel-grouptrial (NCT01262638) was con-
ducted at 11 sites in the United
States. The four treatment arms
included ETC-1002 40, 80, and
120 mg and placebo once daily for
12 weeks. Clinic visits were con-
ducted at weeks –6 (required only
for those washing out of lipid-
altering drugs), –2, –1, 0, 2, 4, 8,
and 12. The protocol and
informed-consent document were
approved by the appropriate insti-
tutional review boards, the study
was conducted according to the
guidelines for Good Clinical Prac-
tice, and study participants under-
went the informed-consent process
prior to the conduct of any study-
related procedures.
Study participant inclusion and exclusion criteria. Eli-
gibility criteria included men and naturally post menopausal
or surgically sterile women age 18 to 80 years with
qualifying LDL-C (130 to 220 mg/dl) and triglycerides
(<400 mg/dl) and a body mass index between 18 and
35 kg/m2. Lipid value qualiﬁcation was determined
following a 6-week washout of all lipid-altering drugs and
supplements, with the baseline LDL-C and triglyceride
values being the means of measurements obtained on two
separate visits prior to randomization. Eligible subjects
were then stratiﬁed, based on triglyceride level, into
“not elevated” (<150 mg/dl) and “elevated” (150 to
<400 mg/dl) triglyceride strata, and were then randomized
to receive, with equal probability (1:1:1:1), ETC-1002
40, 80, or 120 mg or matching placebo once daily for
12 weeks.
Exclusion criteria included a history of diabetes mellitus,
clinically signiﬁcant cardiovascular disease, systolic blood
pressure 140 mm Hg, diastolic blood pressure 95 mm Hg,
clinically signiﬁcant liver disease or dysfunction, alanine
aminotransferase/aspartate aminotransferase >2  the upper
limit normal (ULN) or total bilirubin >1.5  ULN, cli-
nically signiﬁcant renal dysfunction (including calculated
creatinine clearance <60 ml/min), unexplained creatine kinase
>3  ULN, or a hematologic or coagulation disorder
(including hemoglobin <12 g/dl).
Efﬁcacy endpoints. The primary endpoint was the percent
change in LDL-C level from baseline to week 12 in each
ETC-1002 dose group versus placebo. Secondary endpoints
were percent changes in non–high-density lipoprotein
cholesterol (non–HDL-C), apolipoprotein (apo)B, LDL
particle number, total cholesterol, triglycerides, HDL-C,
apoA1, HDL particle number, lipoprotein(a), free fatty
acids, and high-sensitivity C-reactive protein (hsCRP).
Post-hoc endpoints were changes in fasting insulin, diastolic
and systolic blood pressure, and hsCRP.
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laboratory tests were performed after 12-hour overnight fasts
(water only). Medpace Reference Laboratories (Cincinnati,
Ohio), which maintained Part III certiﬁcation by Centers
for Disease Control and Prevention (CDC) Lipid Stan-
dardization Program (9) and accreditation by the College of
American Pathologists (10), was the central laboratory that
performed the analyses. Triglycerides and cholesterol were
measured with enzymatic colorimetric tests (Olympus
AU2700 or AU5400 Analyzer, Olympus, Center Valley,
Pennsylvania), with calibration directly traceable to CDC
reference procedures. ApoB-containing lipoproteins were
precipitated with dextran sulfate, and HDL-C was mea-
sured on the supernatant (11). The Friedewald formula
(12) was used to calculate LDL-C unless triglycerides were
>400 mg/dl, in which case it was measured after preparative
ultracentrifugation (beta quantiﬁcation) (13). Non–HDL-C
was calculated by subtracting HDL-C from total cholesterol.
ApoA1, ApoB, lipoprotein(a), and hsCRP were measured
with rate immunonephelometry (Dade Behring BNII
nephelometer, Siemens Healthcare Diagnostics, Deerﬁeld,
Illinois). Lipoprotein particle number was measured using
proton nuclear magnetic resonance spectroscopy (Lipo-
Science, Inc., Raleigh, North Carolina) (14). Free fatty acids
were measured using an enzymatic photometry assay (Wako
Chemicals USA, Inc., Richmond, Virginia) adapted to
a Randox Daytona instrument (Randox, Ltd., Crumlin,
United Kingdom). Homocysteine was measured on an
Olympus analyzer using an enzymatic photometry assay
(Diazyme Laboratories, Poway, California), and insulin was
measured on an Elecsys_E170 analyzer using an electro-
chemiluminescence immunoassay (Roche Diagnostics Cor-
poration, Indianapolis, Indiana). Investigators were blinded
to lipid, apo, and hsCRP values after subjects were
randomized and dosing was commenced.
Safety endpoints. Safety was assessed by reported adverse
events; physical examination, including vital sign measure-
ment, electrocardiogram readings, weight, and ankle
circumference measurements; and clinical laboratory testing
for safety parameters, including hematology, blood chem-
istry, and urinalysis. Blood pressure was measured in
duplicate 3 minutes apart after the patient had been sitting
quietly for 5 minutes. The relationships between study drug
and adverse events were assessed by the investigator, with
consideration of temporal association and other potential
etiologies.
Statistical methods. This proof-of-concept study was
designed to assess the lipid-altering effects of ETC-1002
and to explore additional parameters that may merit inves-
tigation in future clinical studies. The primary endpoint was
the percent change in LDL-C level from baseline to week 12
in each ETC-1002 dose group versus placebo in the
modiﬁed intent-to-treat (mITT) population, which was
assessed within and across each triglyceride stratum using an
analysis of covariance (ANCOVA) model, with the effects
of treatment and baseline values as covariates to generateleast-squares means and p values. The mITT population
was deﬁned as all randomized subjects who received at least
one dose of study medication with at least one before- and
after-baseline assessment using the last-observation-carried-
forward approach, excluding assessments taken more than 2
days after last dose of study medication. All statistical testing
was 2-sided and conducted at the 5% level of signiﬁcance,
with no adjustment for multiple comparisons. A sample size
of 176 subjects was selected to provide 80% power to detect
a 20% change in LDL-C in each ETC-1002 treatment
group within each triglyceride stratum (n ¼ 22) versus
placebo, assuming an SD of 21% and a dropout rate of 10%.
Assessment of secondary endpoints (non–HDL-C, apoB,
LDL-C particle number, total cholesterol, triglycerides,
HDL-C, apoA1, HDL particle number, lipoprotein[a], free
fatty acids, and hsCRP) and post-hoc analyses (fasting
insulin, diastolic and systolic blood pressures, and hsCRP
[in a relevant subgroup only]) were assessed as with the
primary endpoint, except that post-hoc analyses were
completed in relevant subgroups rather than by triglyceride
stratum. All statistical procedures for the primary and
secondary endpoints were pre speciﬁed prior to database lock
and unblinding; post-hoc analyses were designed following
initial data review and should be viewed as exploratory. Data
for those secondary and post-hoc endpoints that were found
to have been not normally distributed based on graphical
assessment and the Shapiro-Wilk test (triglycerides, apoA1,
lipoprotein[a], hsCRP, and fasting insulin in all subjects
only, and free fatty acids) were summarized with medians
and then assessed using a nonparametric analysis (rank
ANCOVA with p values obtained from the Cochran-
Mantel-Haenszel test). Analyses were performed using
SAS software version 9.1.3 (SAS Institute Inc., Cary, North
Carolina) run in a Windows XP (Microsoft Corporation,
Redmond, Washington) environment. Safety analyses
included all subjects receiving at least one dose of study
medication, and adverse events were coded using the
Medical Dictionary for Regulatory Activities version 13.1.Results
Study subject disposition and baseline demographics.
The study subject disposition is summarized in Figure 1.
Of the 177 individuals randomized, 15% (n ¼ 26)
discontinued prior to completion of the trial, most
commonly due to an adverse event. Among randomized
subjects, the mean age was 57 years, and the body mass
index was 28 kg/m2. Subjects were mostly white (86%),
and almost half were women (45%). Patient characteristics
across treatment groups (Table 1) and triglyceride strata
were generally similar, with the exception of baseline
lipid parameters, which, as expected, differed across
triglyceride strata (nonelevated/elevated triglyceride strata:
LDL-C, 161  21/172  26 mg/dl; triglycerides,
103 30/215 56mg/dl; HDL-C, 57 13/47 10mg/dl)
(data not shown).
Figure 1 Disposition of Subjects
mITT ¼ modiﬁed intent-to-treat; Pop. ¼ population.
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ing the primary endpoint, ETC-1002 decreased LDL-C
levels in a dose-dependent manner (Table 2, Fig. 2).
Within the overall study population, LS mean  SE percent
changes from baseline to week 12 were –17.9  2.2%,
–25.0  2.1%, and –26.6  2.2% in the ETC-1002 40-,
80-, and 120-mg treatment groups, respectively, compared
with –2.1  2.2% in the placebo group (all, p < 0.0001 vs.
placebo). ETC-1002 similarly reduced LDL-C levels at all
doses (all, p < 0.05) across the nonelevated- and elevated-
triglyceride strata (Fig. 2). Maximum LDL-C lowering
appeared to have occurred within 2 weeks (the ﬁrst post-
treatment assessment) and was maintained for the
remainder of the trial (Fig. 2). ETC-1002 reductions in
LDL-C were accompanied by similar reductions in non–
HDL-C, apoB, and LDL particle number at all dose levels
(all, p < 0.0001 vs. placebo). ETC-1002 numerically
decreased triglycerides and increased HDL parameters;
however, these changes were neither consistently statistically
signiﬁcant nor dose related. ETC-1002 also numericallyreduced hsCRP at all doses, but these changes were not
statistically signiﬁcant.
Other cardiometabolic risk factors. A post-hoc, explor-
atory analysis evaluated the effects of ETC-1002 on fasting
insulin, diastolic blood pressure, and hsCRP (Table 3). In all
subjects, treatment with ETC-1002 had minimal effect on
fasting insulin. However, in the subgroup of subjects with
elevated baseline fasting insulin 12 mIU/ml, ETC-1002
40 mg (p ¼ 0.005) and 80 mg (p ¼ 0.03) signiﬁcantly
reduced fasting insulin levels. The ETC-1002 40- and
80-mg groups trended toward a decrease in diastolic blood
pressure of 2.5 mm Hg in all subjects and 5 to 6 mm Hg in
a small subgroup with mildly elevated baseline diastolic
blood pressure (80 mm Hg). ETC-1002 had a similar
effect on systolic blood pressure, though lesser in magnitude
(data not shown). The magnitude of change in hsCRP was
also greater in subjects with elevated hsCRP (2 mg/l) at
baseline. In that subgroup, treatment with ETC-1002
lowered hsCRP by 43% to 63.5% versus a 7.0% reduction
with placebo.
Table 1 Baseline Demographic Characteristics and Cardiometabolic Risk Factors
Characteristic
ETC-1002 Dose
Placebo
(N ¼ 44)
40 mg
(N ¼ 45)
80 mg
(N ¼ 44)
120 mg
(N ¼ 44)
Demographics
Age, yrs 58  9 59  9 57  10 56  10
Women 26 (58%) 21 (48%) 19 (43%) 13 (30%)
Caucasian 38 (84%) 36 (82%) 41 (93%) 37 (84%)
BMI, kg/m2 27  4 29  4 28  3 29  3
Lipids and lipoproteins
LDL-C, mg/dl* 163  25 170  26 165  23 167  22
Non–HDL-C, mg/dl* 193  33 202  32 197  28 201  26
Apolipoprotein B, mg/dl 125  24 129  19 127  20 130  18
LDL particle number, nmol/l 1,706  508 1,878  451 1,732  405 1,858  406
TC, mg/dl* 249  33 252  31 248  25 250  26
Triglycerides, mg/dl* 148  66 158  68 159  74 168  79
HDL-C, mg/dl* 57  14 50  12 51  12 49  11
Apolipoprotein A1, mg/dl 165  29 153  25 156  27 154  20
HDL particle number, nmol/l 36  6 34  6 34  5 33  4
Lipoprotein(a), mg/dl 32  35 29  28 24  25 30  29
Free fatty acids, mmol/l 0.5  0.2 0.5  0.2 0.5  0.2 0.5  0.2
Other cardiometabolic risk factors
hsCRP, mg/ly 1.8 1.9 1.4 1.8
DBP, mm Hg 73  8 78  6 76  6 78  7
SBP, mm Hg 119  11 121  9 119  9 123  9
Insulin, mIU/ml 10  5 10  5 10  4 10  6
Glucose, mg/dl 95  10 97  9 94  9 97  11
HbA1c, % 5.7  0.3 5.7  0.3 5.7  0.3 5.8  0.3
Values are mean  SD or n (%). *Baseline deﬁned as the mean of the values from weeks –1 to 0. yMedian.
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; HbA1c ¼ hemoglobin A1c; HDL ¼ high-density lipoprotein; hsCRP ¼ high-sensitivity
C-reactive protein; LDL ¼ low-density lipoprotein; SBP ¼ systolic blood pressure.
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this trial (Table 4). Approximately three-fourths of subjects
experienced at least one adverse event during the 12-week
treatment period, with headache being the most common.Table 2 Percent Changes From Baseline in Lipids
Parameter
E
40 mg
(n ¼ 42)
Primary endpoint
LDL-C, mg/dl 17.9  2.2*
Secondary endpoints
Non–HDL-C, mg/dl 17.4  2.0*
Apolipoprotein B, mg/dl 14.6  1.8*
LDL particle number, nmol/l 14.8  2.3*
TC, mg/dl 11.5  1.5*
Triglycerides, mg/dlz 14.5y
HDL-C, mg/dl 7.2  2.2
Apolipoprotein A1, mg/dlz 1.0y
HDL particle number, nmol/l 5.7  1.8y
Lipoprotein(a), mg/dlz 0.0
Free fatty acids, mmol/lz 15.0
hsCRP, mg/lz 21
Values are least-squares mean  SE. *p < 0.0001 versus placebo. yp < 0.0
as medians.
HDL ¼ high-density lipoprotein; HDL-C ¼ high-density lipoprotein choles
lipoprotein; LDL-C ¼ low-density lipoprotein cholesterol; TC ¼ total cholesterMyalgia was reported in 4%, 5%, and 7% of subjects in
the ETC-1002 40-, 80-, and 120-mg treatment groups,
respectively, and in none of the placebo-treated subjects.
Further investigation of the seven ETC-1002 subjects, Lipoproteins, and hsCRP
TC-1002 Dose
Placebo
(n ¼ 42)
80 mg
(n ¼ 44)
120 mg
(n ¼ 42)
25.0  2.1* 26.6  2.2* 2.1  2.2
22.7  2.0* 23.0  2.0* 2.3  2.0
18.4  1.8* 22.1  1.8* 0.9  1.8
16.3  2.2* 20.7  2.3* 1.9  2.2
17.8  1.5* 17.1  1.5* 1.4  1.5
12.5 þ1.5 5.5
0.9  2.1 4.4  2.2 2.4  2.2
5.0 3.0 4.0
3.6  1.7 7.3  1.8y 0.4  1.8
0.0 6.0y 0.0
14.5 3.0 4.5
26 20 2
5 versus placebo. zData were not normally distributed and are reported
terol; hsCRP ¼ high-sensitivity C-reactive protein; LDL ¼ low-density
ol.
Figure 2 Percent Changes From Baseline in LDL-C
(A) Least-squares mean percent changes from baseline in low-density lipoprotein cholesterol (LDL-C) in subjects with nonelevated (<150 mg/dl) versus elevated (150 to <400
mg/dl) baseline triglycerides (TG). (B) Unadjusted mean percent change from baseline in LDL-C in all subjects over time. *p < 0.05 versus placebo; yp < 0.0001 versus
placebo. PBO ¼ placebo.
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1159reporting myalgia showed that a single subject receiving
80 mg of ETC-1002 was withdrawn from the trial due to
this adverse event, whereas all other subjects completed
12 weeks of treatment. None of the individuals reporting
myalgia experienced concurrent creatine kinase elevations
>2  ULN.
A minority of subjects (from 7% to 9% across treatment
groups, including placebo) discontinued trial participation due
to one or more adverse events, which included abdominal
discomfort, abdominal pain, and muscle tightness in the ETC-
1002 40-mg group; gastroesophageal reﬂux disease, nausea,
elevated alanine aminotransferase, elevated aspartate amino-
transferase, arthralgia, myalgia, and headache in the 80-mg
group; abdominal distension, nausea, arthralgia, headache,
and pollakiuria in the 120-mg group; and ﬂatulence, pain,
arthralgia, gouty arthritis, muscle spasms, headache, hyperes-
thesia, and somnolence in the placebo group. Approximately
one-third of subjects in the trial experienced at least one adverse
event that was considered by the investigator to have been
related to the study medication, with the lowest rate (32%)
in the ETC-1002 120-mg group and the highest rate (39%)
in the placebo group; none of the adverse events considered
related to the study medication appeared to have demonstrated
a dose-related trend. Adverse events considered by the inves-
tigator to have been related to the study medication included
abdominal discomfort, abdominal distension, abdominal pain,
diarrhea, dyspepsia, nausea, asthenia, increased energy, fatigue,
increased blood creatine kinase, abnormal red blood cell count,
arthralgia, muscle spasms, muscle tightness, musculoskeletal
stiffness, myalgia, dizziness, headache, milia, and macular rash
in the ETC-1002 40-mg group; anemia, visual impairment,
diarrhea, gastroesophageal reﬂux disease, nausea, vomiting,urinary tract infection, decreased hematocrit, increased hepatic
enzyme, increased international normalized ratio, abnormal
prothrombin level, decreased white blood cell count, arthralgia,
myalgia, dizziness, dysgeusia, headache, nightmare, cough, and
rash in the 80-mg group; abdominal distension, abdominal
pain, upper abdominal pain, constipation, dental discomfort,
dyspepsia, nausea, fatigue, hunger, pain, increased blood crea-
tine kinase, increased gamma-glutamyltransferase, arthralgia,
muscle spasms, pain in extremity, headache, paraesthesia, pol-
lakiuria, pruritus, papular rash, and inadequately controlled
blood pressure in the 120-mg group; and abdominal discom-
fort, upper abdominal pain, diarrhea, dyspepsia, ﬂatulence,
nausea, vomiting, peripheral edema, pain, weight increase,
arthralgia, gouty arthritis, muscle spasms, postural dizziness,
headache, hyperesthesia, somnolence, sleep disorder, and
dyspnea in the placebo group. No deaths occurred during the
study, and a single serious adverse event (chest pain) occurred in
a placebo-treated subject.
Assessment of laboratory results for clinically signiﬁcant
trends showed few differences. In the ETC-1002 groups,
mean uric acid was increased by 7% to 16%. Increases in
mean homocysteine (ULN: 15 mmol/l) appeared to have
been dose related (absolute mean changes  SD with
ETC-1002 40, 80, and 120 mg and placebo: þ1.3 
2.1, þ1.9  1.8, þ2.4  2.2, and þ0.2  1.3 mmol/l,
respectively) (data not shown). Mean hemoglobin was also
decreased (absolute mean changes  SD: –0.3  0.5, –0.5
 0.6, –0.6  0.6, and –0.1  0.7 g/dl), with no corre-
sponding changes in white blood cells or platelets (data not
shown). Other safety measures (electrocardiography, vital
signs, weight, ankle circumference, and other parameters
measured on physical examination) did not demonstrate
Table 3 Change From Baseline in Other Cardio-Metabolic Risk Factors
Parameter
ETC-1002 Dose
Placebo40 mg 80 mg 120 mg
Fasting insulin, mIU/ml
All subjects n ¼ 39 n ¼ 40 n ¼ 38 n ¼ 40
Median 0.8 1.5 1.55 0.55
p vs. placebo 0.53 0.3 0.38
Baseline 12 mIU/ml subgroup n ¼ 12 n ¼ 13 n ¼ 12 n ¼ 12
LS mean  SE 5.8  1.8 4.3  1.7 2.4  1.8 1.49  1.8
p vs. placebo 0.005 0.03 0.13
DBP, mm Hg
All subjects n ¼ 42 n ¼ 44 n ¼ 43 n ¼ 43
LS mean  SE 2.5  0.9 2.5  0.9 0.5  0.9 0.1  0.9
p vs. placebo 0.08 0.06 0.79
Baseline 80 mm Hg subgroup n ¼ 8 n ¼ 11 n ¼ 8 n ¼ 14
LS mean  SE 5.9  2.0 4.8  1.7 1.7  2.0 0.8  1.6
p vs. placebo 0.05 0.09 0.73
hsCRP, mg/l
All subjects n ¼ 42 n ¼ 44 n ¼ 43 n ¼ 43
Median 21% 26% 20% 2%
p vs. placebo 0.33 0.15 0.28
Baseline 2 mg/l subgroup n ¼ 18 n ¼ 18 n ¼ 13 n ¼ 15
Median 43% 63.5% 45% 7.0%
p vs. placebo 0.06 0.02 0.25
hsCRP ¼ high-sensitivity C-reactive protein; LS ¼ least squares.
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(data not shown).Discussion
ETC-1002 is an investigational drug that inhibits sterol and
fatty acid synthesis and promotes mitochondrial long-chain
fatty acid oxidation through modulation of hepatic ACL and
AMPK (5). This study was the ﬁrst Phase II study of ETC-
1002 in hypercholesterolemic individuals with or without
elevated triglyceride levels. After 12 weeks, ETC-1002
signiﬁcantly lowered LDL-C levels up to 27% (placebo
reduced LDL-C levels 2%), irrespective of normal to
elevated baseline plasma triglyceride levels. The reduction in
LDL-C with ETC-1002 was accompanied by similar
reductions in non–HDL-C, apoB, and LDL particle
number. Post-hoc analyses suggested that ETC-1002 may
have the potential to reduce hsCRP, blood pressure, and
fasting insulin in certain subgroups. ETC-1002 was gener-
ally safe and well tolerated in the subject population.
Cardiovascular disease remains the leading cause of death
in the United States (15), and its burden is expected to
increase as the population ages and medical costs rise (16). It
has been projected that although the prevalence of cardio-
vascular disease is expected to grow approximately 10%
by 2030, its direct medical costs (in 2008 dollars) will triple
(16). In order to alter the projected course of cardiovascular
disease, improved prevention and early intervention to treat
established risk factors are needed (16). Statins will remain
central to this strategy; however, there is increasing awarenessof the limitations and cautions of statin use. In 2011, the U.S.
Food and Drug Administration (FDA) mandated safety-
labeling changes limiting the use of high-dose (80 mg) sim-
vastatin due to safety concerns of muscle injury or myopathy
(17). Although myopathy is rare, a more widespread problem
is various muscular side effects, such as pain and weakness,
particularly at high doses, resulting in poor tolerability and a
lack of persistence with statin therapy (18). Recently, more
subtle side effects of statin therapy, including an increased risk
for diabetes (19), particularly at higher doses (20), prompted
the FDA tomandate additional safety-labeling warnings (21).
Other than statins, few drugs have been approved for
lowering LDL-C, and their efﬁcacy is modest. This Phase II
study suggests that ETC-1002 may reduce LDL-C levels
more than currently approved nonstatin agents. For example,
ezetimibe is an intestinal cholesterol absorption inhibitor
that has been reported to lower LDL-C by 18% in patients
with primary hyperlipidemia (22). Colesevelam is a bile
acid sequestrant that has been reported to lower LDL-C by
up to 18% (23), whereas extended-release niacin doses up
to 2 g have been reported to lower LDL-C by up to 17%
(24). Finally, fenoﬁbrate, a peroxisome proliferator-activated
receptor alpha activator, was reported to lower LDL-C levels
by approximately 20% in patients with hypercholesterolemia
(25) but may substantially increase LDL-C levels in patients
with hypertriglyceridemia.
The blunting of the LDL-C lowering found with ﬁbrate
administration in patients with hypertriglyceridemia (25) is
in contrast to the modest changes in triglyceride levels
with ETC-1002 in patients with higher triglyceride levels,
Table 4 Safety Overview: Treatment-Emergent AEs
Parameter
ETC-1002 Dose
Placebo
(n ¼ 44)
40 mg
(n ¼ 45)
80 mg
(n ¼ 44)
120 mg
(n ¼ 44)
Overview of AEs
Any AE 34 (76%) 32 (73%) 31 (71%) 33 (75%)
SAE 0 0 0 1 (2%)*
TRAEy 16 (36%) 16 (36%) 14 (32%) 17 (39%)
AE led to
discontinuationz
3 (7%)x 4 (9%)k 3 (7%){ 4 (9%)#
Most common AEs**
Headache 5 (11%) 5 (11%) 7 (16%) 4 (9%)
UTI 4 (9%) 1 (2%) 0 1 (2%)
Nausea 3 (7%) 3 (7%) 4 (9%) 2 (5%)
Diarrhea 3 (7%) 3 (7%) 1 (2%) 3 (7%)
Fatigue 3 (7%) 1 (2%) 1 (2%) 1 (2%)
Cough 2 (4%) 3 (7%) 1 (2%) 1 (2%)
Myalgia 2 (4%) 2 (5%) 3 (7%) 0
Arthralgia 2 (4%) 2 (5%) 1 (2%) 6 (14%)
Bronchitis 0 3 (7%) 1 (2%) 1 (2%)
Pain in extremity 0 0 4 (9%) 1 (2%)
Laboratory
abnormalitiesyy
ALT >3  ULN 0 1 (2%)zz 0 0
AST >3  ULN 0 1 (2%)zz 0 0
CK >5  ULN 0 0 0 0
Total bilirubin
>2  ULN
0 0 0 0
Creatinine >0.5
mg/dl  ULN
0 0 0 0
Values are n (%). *Chest pain. ySome patients experienced more than one AE that was considered
treatment related. zSome patients experienced more than one AE that led to discontinuation.
xAbdominal discomfort, abdominal pain, and muscle tightness. kGastroesophageal reﬂux disease,
nausea, elevated alanine aminotransferase, elevated aspartate aminotransferase, arthralgia,
myalgia, and headache. {Abdominal distension, nausea, arthralgia, headache, and pollakiuria.
#Flatulence, pain, arthralgia, gouty arthritis, muscle spasms, headache, hyperesthesia, and
somnolence. **Those occurring in 5% of patients in any treatment group. yyPre-speciﬁed labo-
ratory abnormalities required conﬁrmation on repeat assessment. zzThis laboratory abnormality
(ALT/AST 4  ULN in a single subject) was considered by the investigator as not related to treat-
ment as it coincided with a conﬁrmed acute cytomegalovirus infection.
AE ¼ adverse event; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase;
CK ¼ creatine kinase; SAE ¼ serious adverse event; TRAE ¼ treatment-related adverse event;
ULN ¼ upper limit of normal; UTI ¼ urinary tract infection.
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of these lipid-regulating compounds. The median percent
changes from baseline in triglycerides were –14.5%, –12.5%,
and þ1.5% in the ETC-1002 40-, 80-, and 120-mg treat-
ment groups, respectively, versus –5.5% in the placebo group,
with no signiﬁcant differences in efﬁcacy in the subgroup
with elevated baseline triglycerides (data not shown). The
limited triglyceride lowering with ETC-1002 observed in the
current study is different from the data from some preclinical
experiments (5); this difference may be due to the relatively
minor role of de novo fatty acid synthesis in affecting plasma
triglyceride levels in humans (26).
Assessment of the effect of ETC-1002 on nonlipid car-
diometabolic risk factors in this study was limited because
entry criteria required well-controlled blood pressure and an
absence of diabetes mellitus. ETC-1002 lowered insulin
levels in a subgroup with baseline levels 12 mIU/ml (a cut
point for identifying insulin resistance in patients withoutdiabetes mellitus) (27). Similarly, ETC-1002 lowered
hsCRP among subjects with baseline hsCRP levels 2 mg/l
(a cut point for identifying increased cardiovascular-disease
risk (28). Finally, ETC-1002 demonstrated a trend toward
blood pressure reduction among those with higher blood
pressure readings at baseline. The efﬁcacy and safety of ETC-
1002 in combination with statins and other lipid-regulating
drugs were not tested in this trial and are currently
unknown; these will be assessed in future clinical trials.
ETC-1002 treatment was not associated with serious side
effects and had a proﬁle that was similar to placebo in terms of
the number of subjects with any AE, serious AEs, AEs that
were considered related to treatment, and withdrawals due to
AEs.Many common AEs were also similarly distributed across
all treatment groups, including placebo.Although an increase in
homocysteine was observed, the magnitude of change with
ETC-1002 appears to be about half (29) of that seen with
fenoﬁbrate, and the increase was not accompanied by a corre-
sponding increase in creatinine or reduction in triglycerides, as
would be expected with the use of a ﬁbrate.
Study limitations. This study included relatively few
subjects, who were treated for only 3 months with ETC-
1002. Subjects with severe diseases were excluded.
Comprehensive characterization of the safety and efﬁcacy of
ETC-1002 will require additional studies.
Conclusions
These results suggest that ETC-1002 monotherapy may be
a novel therapeutic approach for LDL-C lowering that may
provide efﬁcacy in lowering atherogenic lipoproteins greater
than that of currently available nonstatin therapies. The
effects of ETC-1002 on other cardiometabolic risk factors
merit investigation in future studies.Acknowledgments
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